Results 271 to 280 of about 710,958 (307)
Some of the next articles are maybe not open access.
Immunotherapy for non-small cell lung cancer
JAAPA, 2019ABSTRACT Immunotherapy is a new genre of treatment for patients with advanced cancer. Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC). Clinical trials using several combinations of immunotherapy are underway to help to determine the best treatment ...
openaire +2 more sources
Gemcitabine in non-small cell lung cancer
Lung Cancer, 1995The pyrimidine antimetabolite gemcitabine is an analogue of cytosine arabinosid. Gemcitabine is well tolerated when given in doses of 1000-1250 mg/m2 weekly x 3 followed by 1 weeks rest, with mild myelosuppression as the major toxicity. In five studies, including a total of 250 patients with previously untreated non-small cell lung cancer (NSCLC ...
openaire +2 more sources
Ifosfamide in Non-Small Cell Lung Cancer
Oncology, 2003In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of 20–25%.
C, Boni, F, Zanelli
openaire +2 more sources
Pneumonectomy for non-small cell lung cancer
Surgery Today, 2012To assess the mortality, complications and major morbidity of pneumonectomy for non-small cell lung cancer (NSCLC) and to establish the importance of various prognostic factors.We reviewed retrospectively the hospital records of 71 consecutive patients who underwent pneumonectomy for NSCLC between 1992 and 2007 to evaluate the significance of risk ...
Yoshinobu, Ichiki +3 more
openaire +2 more sources
Vinorelbine for non-small cell lung cancer
Expert Opinion on Drug Safety, 2010Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs.
Maria Carmela, Piccirillo +7 more
openaire +2 more sources
Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry-Anti-Cancer Agents, 2005The treatment of advanced non-small-cell lung cancer (NSCLC is based on the combination of platin and one of the following agents: taxanes, gemcitabine, vinorelbine or irinotecan. There are no significant differences in efficacy among these combinations suggesting that the maximum efficacy has been reached.
Pascal, Sève, Charles, Dumontet
openaire +2 more sources
Gefitinib in non-small cell lung cancer
Expert Opinion on Pharmacotherapy, 2005Gefitinib (Iressa), an orally-active tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR), is the first approved molecular-targeted drug for the management of patients with advanced non-small cell lung cancer (NSCLC). Two Phase II trials (IDEAL [Iressa Dose Evaluation in Advanced Lung Cancer]-1 and -2), evaluated the efficacy of ...
Kenji, Tamura, Masahiro, Fukuoka
openaire +2 more sources
Paclitaxel for non-small cell lung cancer
Expert Opinion on Pharmacotherapy, 2004Paclitaxel, a tubulin-binding agent, is widely used for the treatment of non-small cell lung cancer (NSCLC). The combination of paclitaxel and a platinum compound is an approved regimen for the treatment of advanced NSCLC. The dose-limiting toxicity of paclitaxel is myelosuppression when administered on a prolonged infusion schedule, whereas neuropathy
Sakkaraiappan, Ramalingam +1 more
openaire +2 more sources
Imaging of Non–Small Cell Lung Cancer
Radiologic Clinics of North America, 2005Radiologic evaluation is an important component of the clinical staging evaluation of lung cancer and can greatly influence whether the patient is treated with surgical resection, radiation therapy, chemotherapy, or a combination of these modalities. In addition to staging, the radiologic evaluation of the patient undergoing treatment and subsequent ...
Reginald F, Munden, John, Bruzzi
openaire +2 more sources
Angiogenesis in non-small cell lung cancer
Seminars in Thoracic and Cardiovascular Surgery, 2004Two processes are necessary for a tumor colony to grow and become invasive: angiogenesis and basement membrane degradation. Angiogenesis is the formation of new blood vessels from the endothelium of existing vasculature, in response to the metabolic demand of the tumor.
openaire +2 more sources